A process evaluation of Ontario, Canada’s 2023–24 older-adult RSV vaccination program
Respiratory syncytial virus (RSV) is a major cause of respiratory illness in older adults. During the 2023–2024 respiratory season, Ontario was the first and only province in Canada to launch a publicly funded RSV vaccination program for older adults. A process evaluation of the program was complete...
Saved in:
| Main Authors: | Reed Morrison, Janice Sarmiento, Jamie Park, Gillian Lim, Christina Renda, Michael Whelan, Allison McGeer, Tara Harris, Sarah E. Wilson |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2025-12-01
|
| Series: | Human Vaccines & Immunotherapeutics |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/21645515.2025.2550089 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Preventing RSV Infection in Children: Current Passive Immunizations and Vaccine Development
by: Pius I. Babawale, et al.
Published: (2025-01-01) -
Optimal implementation of an Ontario nirsevimab program for respiratory syncytial virus (RSV) prophylaxis: Recommendations from a provincial RSV expert panel
by: Bosco Paes, et al.
Published: (2024-12-01) -
The impact of nirsevimab prophylaxis on RSV hospitalizations: a real-world cost-benefit analysis in Tuscany, Italy
by: Vieri Lastrucci, et al.
Published: (2025-07-01) -
Epidemiological and Clinical Characteristics of Adult RSV Infections: A Retrospective Analysis at University Hospital Center Zagreb (2022–2024)
by: Antonio Perčinić, et al.
Published: (2025-03-01) -
Cost-Effectiveness and Public Health Impact of Universal Prophylaxis with Nirsevimab Against Respiratory Syncytial Virus (RSV) Infections in all Infants in Japan
by: Shinichi Noto, et al.
Published: (2025-03-01)